Therapy for acute heart failure syndromes

Curr Cardiol Rep. 2009 May;11(3):192-201. doi: 10.1007/s11886-009-0028-6.

Abstract

The pharmacologic management of acute heart failure syndromes (AHFS) has changed little over the past 15 years. Traditional therapies, such as nitrates and loop diuretics, remain the mainstay of therapy, with inotropes reserved for patients who present in shock or an advanced low-output state. We review the use of these therapies in AHFS with added insights from recent clinical trials and registry data.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Cardiotonic Agents / administration & dosage*
  • Digoxin / administration & dosage
  • Diuretics / administration & dosage*
  • Dobutamine / administration & dosage
  • Drug Therapy, Combination
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy*
  • Heart Failure / mortality*
  • Humans
  • Male
  • Milrinone / administration & dosage
  • Mineralocorticoid Receptor Antagonists / administration & dosage
  • Morphine / administration & dosage
  • Nitroprusside / administration & dosage
  • Practice Guidelines as Topic
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Syndrome
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Diuretics
  • Mineralocorticoid Receptor Antagonists
  • Nitroprusside
  • Dobutamine
  • Digoxin
  • Morphine
  • Milrinone